This study demonstrated that DG suppressed Aβ1–42-induced oxidative stress and mitochondrial dysfunction partially via induction of PGC-1α and alleviated Aβ1–42-induced cognitive impairment, suggesting DG might be developed into a promising drug for treatment of AD. The gene discussed is PPARGC1A; the disease is Cognitive impairment.